Interim Report January – September 2024

"During the year, we have made great progress, as those of you who have followed our reports have surely seen. At the same time as we have streamlined our cost structure, we have placed great focus on completing new products in which we see great potential for the coming years. We are convinced that these innovations will meet a strong market demand."."

July - september 2024

Net sales increased by 17% and amounted to SEK 19.4 (16.6) million.
The gross margin amounted to 47% (29%).
EBITDA amounted to -0.2 (-8.6) MSE
The profit after tax amounted to -4.5 (-10.9) MSEK.
Profit after tax per share before and after dilution amounted to -0.10 (-0.25) SEK.

January - september 2024

Net sales fell by 9% and amounted to SEK 59.2 (65.3) million.
The gross margin amounted to 40% (40%).
EBITDA amounted to -9.2 (-10.7) MSEK.
The profit after tax amounted to -15.0 (-15.5) MSEK.
Profit after tax per share before and after dilution amounted to -0.34 (-0.35) SEK.

Significant events during and after the reporting period

Ortivus extends credit framework agreement with its main owner Ponderus Invest AB to SEK 25 million. After the reporting period, the credit line was extended until 31 December 2025.
After the end of the reporting period, the company applies to Nasdaq for the company's shares to be listed on the First North Growth Market instead of, as now, on Nasdaq Stockholm. This is part of the activities the company carries out to reduce the cost mass.

Group's key figures

	jul-sep 2024	jul-sep 2023	jan-sep 2024	jan-sep 2023	jan-dec 2023
kSEK
Net sales	19 412	16 572	59 151	65 270	84 678
Gross margin	47%	29%	40%	40%	37%
EBITDA	- 186	-8 636	-9 238	-10 661	-11 860
Operating results	-3 073	-11 041	-12 933	-15 219	-17 612
Profit after tax	-4 530	-10 905	-15 015	-15 467	-18 245
Equity ratio (%)	3,5%	28,4%	3,5%	28,4%	23,8%
Earnings per share, SEK before and after dilution	-0,10	-0,25	-0,34	-0,35	-0,41
Equity per share, SEK	0,05	0,46	0,05	0,46	0,80

From the CEO

The transformation continues!

During the year, we have made significant progress, which those of you who have followed our reports have likely noticed. While streamlining our cost structure, we have also focused intensely on finalizing new products that we see great potential in for the coming years. We are confident that these innovations will meet strong demand in the market. Our extensive deliveries, especially the national MobiMed ePR* project in Estonia, are proceeding as planned. During the quarter, we prepared for the final phase, with rollout scheduled to begin as early as Q4. In several of our markets, we have also initiated discussions about expanding our customer agreements, which further strengthens our long-term customer relationships.

Ortivus plays a central role in the critical work being done to make healthcare more efficient and reduce waiting times, where MobiMed ePR provides significant value by giving emergency medical services better data for analysis and improvement. This is crucial for our customers at a time when many face economic challenges. With MobiMed, our ambulance customers can implement best practices, thus continuously improving quality throughout the healthcare chain. We are also seeing a growing demand for our solutions in primary and home healthcare. Today, several of our customers use our products to provide local and homebased care effectively. With overcrowded hospitals, it is often both preferable and better for patients to receive care at home. In a recently concluded pilot project with one of our Nordic customers, the results clearly showed that patients prefer home care when possible. The evaluation of the project is expected to provide us with valuable insights in Q1 2025, which we can greatly benefit from going forward. In Sweden, our customer Region Jämtland also uses MobiMed within primary and home healthcare, which is particularly important in a region like Jämtland with large distances. For the residents of Jämtland, this means better access to care while the region can optimize resource use. During the quarter, we also placed a strong focus on Apple's iOS ecosystem, and the upcoming rollout in Estonia is just the beginning. Interest in iOS has grown globally, with our customers increasingly using iPads in combination with MobiMed ePR. It is clear that our customers and prospective clients see Apple's ecosystem as a highly interesting path forward.

At Ortivus, we are also convinced of the benefits of iOS technology capabilities such as authentication, speech-to-text, camera, video conferencing and Apple Intelligence. We see how the combination of MobiMed ePR and the iOS ecosystem provides both technical and financial advantages for our customers. Ortivus has the ambition to make full use of these opportunities.

The quarter in numbers

We closed the third quarter with liquidity of 2.1 MSEK. This is a temporarily low level, and our cash position will be significantly strengthened in the coming months, as much of our invoicing occurs at the end of the year. Additionally, our major project deliveries in Estonia and Jönköping are soon to be completed, which will contribute positively to cash flow in both the short and long term. During the quarter, we have also temporarily held more capital in accrued income and accounts receivable, but we expect these to return to normal levels next quarter, further strengthening our liquidity. Our gross margin for the quarter was 47%, and EBITDA for the period was -0.2 MSEK—a significant improvement compared to the same period last year, which was -8.6 MSEK. It is also encouraging to see that our costs have decreased by 23% for the guarter and 12% for the year to date, while our revenues for the period have developed positively, an improvement of nearly 3 MSEK compared to the same period last year. The Board assesses that we now have a stable financial situation, providing us with a solid foundation to continue steering the business in the right direction. In Q4 2024, the Group will launch a transition to a new ERP system, which will, over time, improve efficiency and reduce costs. The work on this system transition has been ongoing since April 2024.

Finally, I want to extend my sincere thanks to the team, the Board, and you, our shareholders, for your continued trust. I look forward to an exciting and successful autumn and to reconnecting soon!

^* ePR=Electronic Patient Record

The group's development January – Sep 2024

Financial development

Net sales for the quarter amounted to 19.4 (16.6) MSEK, and for the period to 59.2 (65.3) MSEK. The quarterly improvement is due to revenues in the UK approaching the agreed levels after being reduced following the cyberattack. The lower revenues for the period are attributable to lower hardware sales in the Nordic region during the first half of the year. The gross margin for the quarter was 47% (29%) and 40% (40%) for the period. The sharp increase is explained by the company now approaching normal operations after last year's issues. Operating expenses for the quarter amounted to 12.2 (15.9) MSEK and 36.4 (41.2) MSEK for the period. The operating result for the quarter was -3.1 (-11.0) MSEK and -12.9 (-15.2) MSEK for the period. EBITDA was -0.2 (-8.6) MSEK for the quarter and -9.2 (-10.7) MSEK for the period. The cost reduction measures implemented are starting to show in the operating expenses, which have decreased by 23.3% for the quarter and 11.6% for the period. Depreciation of intangible and tangible assets was 2.9 (2.4) MSEK for the quarter and 3.7 (4.6) MSEK for the period. Capitalization of development costs amounted to 0.8 (2.7) MSEK for the quarter and 1.5 (13.1) MSEK for the period. The result after tax for the quarter was -4.5 (-10.9) MSEK and -15.0 (-15.5) MSEK for the period, corresponding to earnings per share before and after dilution of -0.10 (-0.25) SEK for the quarter and -0.34 (-0.35) SEK for the period.

Cash flow and liquidity

Operating activities generated a cash flow of -15.6 (-6.3) MSEK for the quarter and -20.9 (-0.9) MSEK for the period. This change is due to lower accrued license revenues, with the majority of license revenues being invoiced in Q4. Cash flow from investing activities amounted to -1.3 (-2.7) MSEK for the quarter and -2.0 (-13.1) MSEK for the period. Cash flow from financing activities was 16.0 (6.2) MSEK for the quarter and 23.7 (7.3) MSEK for the period. The Group's total cash flow for the quarter was -0.9 (-2.8) MSEK and 0.8 (-6.7) MSEK for the period. Cash and cash equivalents at the end of the period amounted to 2.1 MSEK, compared to 1.3 MSEK at the end of 2023. It is the board's assessment that Ortivus has a financing situation sufficient for the company's continued operation.

Financial position

Assets: Investments in intangible and tangible fixed assets amounted to 27,775 (28,575) MSEK at the end of the quarter. At the period's end, inventory stood at 9.5 (17.0) MSEK, and accounts receivable at 6.5 (8.8) MSEK. Equity and Liabilities: The Group's equity amounted to 2.4 (20.4) MSEK at the end of the period, with an equity ratio of 3% (28%). The Group's long-term liabilities at the period's end were 2.1 (13.2) MSEK, of which right-of-use assets under IFRS 16 accounted for 1.3 (2.5) MSEK, and deferred revenue for licenses and warranties 0.9 (9.7) MSEK. The Group's current liabilities totaled 63.9 (34.2) MSEK, including loans of 34.4 (8.0) MSEK, customer advances of 7.2 (3.6) MSEK, and lease liabilities under IFRS 16 amounting to 1.8 (2.0) MSEK. The loan from Ponderus Invest is classified here as short-term to reflect the Group's ambition to gradually repay it, even though the credit facility extends beyond the next 12 months.

The group

The group consists of the parent company Ortivus AB ( publ ), corporate no. 556259–1205, and the subsidiaries Ortivus UK Ltd, corporate no. 03558696, Ortivus MobiMed AB, org. no. 556593–0707. Ortivus MobiMed ApS, CVR 43419110 is dormant. All subsidiaries are wholly owned.

Staff

The number of employees in the group at the end of the period amounted to 32 (44) people, of which 2 (2) are in the parent company. Broken down by country, the number of employees in Sweden was 26 (39) and outside Sweden 6 (5). The proportion of women in the group was 28%.

Transactions with related parties

The existing line of credit from Ponderus Invest AB has been increased to SEK 25.0 million and extended to 31 December 2025. Ponderus Invest AB owns 25.4% of the shares as of 30 September 2024 and is represented on the board. The credit runs at a market interest rate of 8% upon utilisation.

Shares, share capital and shareholders

Ortivus A and B shares are listed on the NASDAQ Stockholm Small Cap list. The number of shares as of September 30 amounted to 44.3 million shares divided into 1.7 million A shares and 42.6 million B shares. The number of shareholders amounted to 1,312, of which four directly and indirectly hold shares corresponding to five percent or more of the voting or capital share in the company. The company's market value at the end of the period amounted to SEK 75.6 (135.5) million.

Forward-looking statements

All forward-looking statements in this report are based on the company's best judgment at the time of the report. Such statements, like all forward-looking statements, contain risks and uncertainties, which may mean that the actual outcome will be different. Except as required by applicable law, forward-looking statements speak only as of the date they are made and Ortivus undertakes no obligation to update any of them in light of new information or future events. Ortivus does not provide forecasts.

Miscellaneous

The parent company Ortivus AB (publ) operates on a global market within sales and service. The parent company also includes group-wide operations. The parent company's net sales during the quarter amounted to SEK 6.1 (6.6) million. Operating profit amounted to SEK 3.7 (1.0) million. Cash and cash equivalents at the end of the first period amounted to SEK 0.8 (0.0) million. During the quarter, the parent company carried out a write-down of shares in group companies of SEK 50 million. This is as a result of shareholder contributions that were given to subsidiaries during the second quarter of 2024. The write-down does not affect the group, but only the parent company's equity and the parent company's profit before tax. The measure has no impact on liquidity

Ortivus selection committee 2024/25

In November, the largest owners appointed a nomination committee for the annual general meeting on 8 May 2025. The members are Anna-Carin Strandberg, Peter Edwall, Konstantin Papaxanthis and Pär-Ola Adolfsson.

Financial calendar

14 February 2025 report for the fourth quarter and full year 2024.

26 March 2025 annual report.

8 May 2025 report for the first quarter of 2025.

8 May 2025 annual general meeting.

Financial information

Ortivus AB (publ) is listed on Nasdaq Stockholm, Small Cap. The information in this report is published in accordance with the EU Market Abuse Regulation and the Securities Market Act. The information was provided by the contact persons below for publication on 8 November 2024, at 08:30. Financial reports and press releases are published in Swedish and English and are available at ortivus.com

This report has been reviewed by the company's auditor

This report has been reviewed by the company's auditor For further information: Gustaf Nordenhök, CEO, telephone 08 446 45 00 or e-mail [email protected] , Johan Wewel, CFO, telephone 08 446 45 00 or e-mail [email protected].

Assurance

The board and managing director assure that the interim report provides a fair overview of the parent company's and the group's operations, position and results, and describes significant risks and uncertainty factors that the parent company and the group are facing.

Danderyd, 8 november 2024 Ortivus AB (publ)

Chairman of the board Board member Board member

authorized accountant, BDO Mälardalen AB

Board member CEO

Auditor's review report

Ortivus AB (publ), org.nr 556259-1205

Introduction

We have performed a general review of the interim financial information in summary (the interim report) for Ortivus AB as of 30 September 2024 and the nine-month period ending on that date. It is the board and the CEO who are responsible for preparing and presenting this interim report in accordance with IAS 34 and the Annual Accounts Act. Our responsibility is to express a conclusion about this interim report based on our summary review.

The focus and scope of the review

We have performed our review in accordance with the International Standard on Review Engagements ISRE 2410 Review of Interim Financial Information by the Company's Appointed Auditor. A summary review consists of making inquiries, primarily of persons responsible for financial and accounting matters, performing analytical review and performing other summary review procedures. A review has a different focus, and a significantly smaller scope, compared to the focus and scope of an audit, according to International Standards on Auditing and good auditing practice in general.

Conclusion

Based on our review, no circumstances have come to light that give us reason to consider that the interim report is not, in all material respects, prepared for the group in accordance with IAS 34 and the Annual Accounts Act and for the parent company in accordance with the Annual Accounts Act.

Stockholm on 8 november 2024 BDO Mälardalen AB

Beata Lihammar Certified public accountant

Financial reports, group

The group's report on comprehensive income in summary

Amount in kSEK	july-sep 2024	july-sep 2023	jan-sep 2024	jan-sep 2023	jan-dec 2023
Net sales	19 412	16 572	59 151	65 270	84 678
Cost of goods & services sold	-10 305	-11 725	-35 635	-39 273	-53 240

Gross profit	9 107	4 847	23 516	25 997	31 438
Gross margin	47%	29%	40%	40%	37%
Selling expenses	-7 058	-11 219	-17 755	-25 107	-25 976
Administration costs	-3 236	-2 388	-9 449	-8 062	-11 724
Research and development costs	-2 153	-1 883	-8 873	-6 722	-9 539
Other operating income	246	-	246	427	45
Other operating costs	20	-398	-619	-1 752	-1 856

Operating results	-3 073	-11 041	-12 933	-15 219	-17 612
Operating margin	-16%	-67%	-22%	-23%	-21%
Results from shares in group companies	-34	-	-34	-	-
Financial net	-1 419	138	-1 987	-197	-578

Profit before tax	-4 526	-10 903	-14 954	-15 416	-18 190
Current tax	-4	-2	-61	-51	-55
Profit after tax	-4 530	-10 905	-15 015	-15 467	-18 245

Items that can be transferred to the period's results
Translation differences	-182	-268	91	426	115
Total profit for the period	-4 711	-11 173	-14 923	-15 041	-18 130
Profit after tax attributable to the parent company's shareholders	-4 530	-10 905	-15 015	-15 467	-18 245
Total profit for the period attributable to the parent company's shareholders	-4 711	-11 173	-14 923	-15 041	-18 130

Report on financial position in summary

Amount in kSEK	2024-09-30	2023-09-30	2023-12-31
Fixed assets
Intangible assets	23 574	22 047	23 740
Tangible assets	4 201	6 528	5 791
Financial fixed assets	4 000	4 000	4 000
Total fixed assets	31 775	32 575	33 531
Current assets
Inventory	9 510	16 992	12 767
Accounts receivable	6 529	8 834	15 764
Other claims	5 267	1 626	1 275
Prepaid expenses and accrued income	13 236	10 655	8 080
Liquid funds	2 122	1 165	1 289
Total current assets	36 664	39 272	39 175
Total assets	68 439	71 847	72 706
Equity	2 381	20 393	17 305
Provisions	61	4 091	1 055

Long-term liabilities Prepaid license and warranty revenue	864	9 699	8 545
Loan	-	1 000	1 500
Lease liabilities	1 258	2 490	2 074
Total long-term liabilities	2 122	13 189	12 119

Current liabilities
Advances from customers	7 191	3 551	4 726
Accounts payable	4 820	6 069	9 029
Short-term loans	34 414	8 000	9 300
Other debts	3 171	1 803	2 475
Lease liabilities	1 797	1 950	1 907
Accrued costs and prepaid income	12 482	12 801	14 790
Total current liabilities	63 875	34 174	42 227
Total liabilities and equity	68 439	71 847	72 706

Group report on changes in equity

Amount in kSEK	2024-09-30	2023-09-30	2023-12-31
Opening balance	17 305	35 434	35 435
This year's results	-14 923	-15 041	-18 130
Closing balance	2 381	20 393	17 305

The group's cash flow report in summary

Amount in kSEK	july-sep 2024	july-sep 2023	jan-sep 2024		•
Profit before tax	-4 492	-10 903	-14 920	-15 416	-18 190
Adjustment for items not included in the cash flow	805	1 724	1 871	3 417	4 417
Cash flow from current operations before changes in working capital	-3 687	-9 179	-13 049	-11 999	-13 773
Cash flow from change in working capital	-11 962	2 884	-7 803	11 070	13 743
Cash flow from current operations	-15 649	-6 295	-20 852	-929	-30
Cash flow from investment activities	-1 260	-2 672	-1 987	-13 051	-15 051
Cash flow from financing activities	15 996	6 184	23 672	7 259	8 743
Cash flow for the period	-913	-2 783	833	-6 721	-6 338
Liquid funds at the end of the period	2 654	4 019	1 288	7 597	7 597
Exchange rate difference in cash and cash equivalents	381	-71	1	289	30
Liquid funds at the end of the period	2 122	1 165	2 122	1 165	1 289

Financial reports parent company

The parent company's report on the results in summary

Amount in kSEK	july-sep 2024				jan-dec 2023
Net sales	6 075	6 579	10 786	9 659	11 564
Gross profit	6 075	6 579	10 786	9 659	11 564
Gross margin	100%	100%	100%	100%	100%
Selling expenses	-	-113	-	-200	-391
Administration costs	-2 436	-4 872	-8 660	-7 195	-9 744
Research and development costs	-	-60	-	-65	-90
Other operating income	13	-	13	-	597
Other operating costs	-	-499	-63	-889	-1 360
Operating results	3 652	1 035	2 076	1 310	576
Operating margin	60%	16%	19%	14%	5%
Results from shares in group companies	-50 034	-	-50 034	-	-
Financial net	-624	-901	-2 021	-967	-241
Profit before tax	-47 006	134	-49 979	343	335
Tax	-	-	-	-	-
Profit after tax	-47 006	134	-49 979	343	335

The parent company's report on financial position in summary

Amount in kSEK	2024-09-30	2023-09-30	2023-12-31
Fixed assets
Intangible assets	514	-	-
Shares in group companies	60 009	60 316	60 316
Total fixed assets	60 523	60 316	60 316
Current assets
Accounts receivable	6 914	173	140
Claims on group companies	14 499	41 612	45 457
Tax claim	620	-	-
Other claims	152	3	164
Prepaid expenses and accrued income	604	2 010	810
Liquid funds	768	9	210
Total turnover credits	23 557	43 807	46 781
Total assets	84 080	104 123	107 097
Own capital	31 707	81 698	81 686
Current liabilities
Advances from customers	750	671	475
Accounts payable	1 029	88	1 900
Short-term loan	33 664	7 000	9 300
Liabilities to group companies	14 709	13 367	12 869
Other debts	628	96	95
Accrued costs and prepaid income	1 593	1 203	772
Total current liabilities	52 372	22 425	25 411
Total liabilities and equity	84 080	104 123	107 097

The parent company's report on changes in equity

Amount in kSEK	2024-09-30	2023-09-30	2023-12-31
Opening balance	81 686	81 355	81 351
This year's results	-49 979	343	335
Closing balance	31 707	81 698	81 686

Note 1 Accounting principles

This interim report for the group has been prepared in accordance with IAS 34 Interim reporting and the Annual Accounts Act. The interim report for the parent company has been prepared in accordance with the Annual Accounts Act. The same accounting and valuation principles for the group and the parent company have been applied as in the most recently issued annual report. Important estimates and judgments appear in note 29 in the annual report for 2023. No changes have been made to these that could have a significant impact on the current interim report. New standards, amendments and interpretations effective from 1 January 2024 or later have had no impact on this financial report.

Note 2 Significant risk and uncertainty factors

Through its operations, Ortivus is exposed to many types of risks. The board's work with risk issues appears in the Corporate Governance Report in the company's annual report for 2023, where a more detailed description of the financial risks can be found in note 26.

Note 3 Distribution of income

The group has only one segment that is reflected in its entirety in the group's financial reports. Revenues are distributed by geography according to the table below.

	july-sep 2024	july-sep 2023	jan-sep 2024	jan-sep 2023
The Nordic countries	11 969	11 297	32 481	39 599
Rest of Europe	7 314	4 978	25 501	23 621
The rest of the world	129	297	1 169	2 050
AMOUNT	19 412	16 572	59 151	65 270

Note 4 Alternative key figures

Ortivus applies the European Securities and Markets Authority's (ESMA's) guidelines for so-called alternative performance measures (APM). An APM is a financial measure of historical or future profit development, financial position or cash flow that is not defined or specified in IFRS. The Company presents a number of alternative key figures in the report, the definition of which appears in the section "Definitions of key figures".

Definitions of key figures

Gross margin

Gross profit as a percentage of net sales. The company believes that key figures provide

a deeper understanding of the Company's profitability Amount in kSEK	july-sep 2024	july-sep 2023	jan-sep 2024	jan-sep 2023	jan-dec 2023
Gross profit	9 107	4 847	23 516	25 997	31 438
Net sales	19 412	16 572	59 151	65 270	84 678
Gross margin	47%	29%	40%	40%	37%

Operating margin

Operating profit as a percentage of net sales. The Company believes that key figures provide a deeper understanding of the company's profitability

of the company's profitability	july-sep	july-sep	jan-sep	jan-sep	jan-dec
Amount in kSEK	2024	2023	2024	2023	2023
Operating results	-3 073	-11 041	-12 933	-15 219	-17 613
Net sales	19 412	16 572	59 151	65 270	84 678
Operating margin	-16%	-67%	-22%	-23%	-21%

EBITDA

Operating profit before net interest, tax, depreciation of tangible and intangible fixed assets.

The Company believes that the key figure provides a deeper understanding of the Company's profitability

Amount in kSEK	july-sep 2024	july-sep 2023	jan-sep 2024	jan-sep 2023	•
Profit before tax	-4 526	-10 903	-14 954	-15 416	-18 190
Financial net	-1 453	-138	-2021	-197	-578
Depreciation	2 887	2 405	3 695	4 558	5 752
EBITDA	-186	-8 636	-9 238	-10 661	-11 860

Solidity

Equity as a percentage of total assets. Equity ratio shows what proportion of the balance sheet total is made up of equity and has been included so that investors can form a picture of the Company's capital structure

Amount in kSEK	july-sep 2024	, , ,			jan-dec 2023
Equity	2 381	20 393	2 381	20 393	17 305
The balance sheet	68 439	71 847	68 439	71 847	72 706
Solidity	3%	28%	3%	28%	24%

Earnings per share

Profit after tax divided by the average number of shares for the period

Amount in kSEK	july-sep 2024	july-sep 2023		, ,	jan-dec 2023
Profit after tax	-4 530	-10 905	-15 015	-15 467	-18 245
Average number of shares in thousands for the period	44 307	44 307	44 307	44 307	44 307
Earnings per share	-0,10	-0,25	-0,34	-0,35	-0,41

Equity per share

Equity at the end of the period divided by the number of shares at the end of the period. The company believes that the key figure provides a deeper understanding of the company's profitability.

Amount in kSEK	30-sep 2024	•
Equity at the end of the period	2 381	20 393	17 305
Number of shares at the end of the period	44 307	44 307	44 307
Equity per share	0,05	0,46	0,39

Ortivus product family

MobiMed ePR

An electronic patient record system for intuitive documentation of treatment and events. It enables critical information sharing in real time and streamlines workflows. MobiMed ePR can be integrated with hospital records, national healthcare registers and personal data registers. With integrated decision support, access to patient history and treatment guidelines, MobiMed increases ePR efficiency and security.

MobiMed Monitor

A modular, user-friendly and robust solution for monitoring vital parameters and ECG outside the hospital. The system is flexible and can be adapted to an organisation's needs. The fact that the MobiMed Monitor is modular means that the paramedics only need to bring the necessary equipment to the patient, which minimises heavy lifting.

MobiMed enRoute

An intuitive, user-friendly and optimised system for case management and navigation that meets the specific needs of personnel in the ambulance and rescue services. With the right information at the right time, MobiMed enRoute helps maintain control so ambulances can reach accident sites as quickly as possible.

MobiMed FleetCtrl

A software application tailored for ambulance and rescue service personnel. The application offers functions for easy control and maintenance of the entire vehicle fleet, for example. Users can check fuel levels, schedule inspection dates and ensure proper packing of medicine bags. FleetCtrl facilitates documentation and improves communication.

MobiMed Life

MobiMed Life consists of different models of stand-alone defibrillators, from simple automated external defibrillators (AEDs) designed for public safety, to manual advanced defibrillators intended for healthcare professionals.

Upcoming financial reports Feel free to visit www.ortivus.com

For more information

Gustaf Nordenhök, CEO, phone +468-446 45 00 or Email: [email protected] Johan Wewel, CFO, phone +468-446 45 00 or Email: [email protected]

Ortivus AB Box 713 Svärdvägen 19 182 33 Danderyd Sweden

Phone: + 46 8 446 45 00 Fax: + 46 8 446 45 19 Email: [email protected]

AI Terminal

Ortivus

3186_10-q_2024-11-08_063e1293-d4cf-4ab9-859f-12eafd21ce39.pdf